Skip to main content

Table 3 Treatment and outcome

From: Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis

Characteristic

n/Na (%)

Characteristic

n/Na (%)

No treatment

99/655 (15)

Other treatment modalities

 

First line therapy

434/539 (81)

 Neurosurgical intervention

30/230 (13)

Second line therapy

144/539 (27)

 Anti-epileptic medication

14/106 (13)

Third line therapy

49/539 (9)

 Hormonal substitution

18/227 (8)

Overall treatment

 

Follow-up, yr., mean (SD)

4.4 (SD 3.15)

 Corticosteroids

546/655 (83)

Outcome

 

 Methotrexate

105/655 (16)

 Remission

126/415 (27)

 Azathioprine

54/655 (8)

 Improvement

147/415 (32)

 (Hydroxy) chloroquine

24/655 (4)

 Stable disease

100/415 (22)

 Mycophenolate mofetil

12/655 (2)

 Deterioration

19/415 (4)

 Cyclosporine A

10/655 (2)

 Mortality

42/826 (5)

 Cyclophosphamide

40/655 (6)

  

 TNF-alpha antagonists

24/655 (4)

Favourable outcome per treatment group

Treatment switches

 

 First line therapy

161/227 (71)

 First to second or third line

88/363 (24)

 Second line therapy

47/85 (55)

 Second to third line

14/104 (13)

 Third line therapy

7/18 (39)

 Between third line

7/23 (30)

  
  1. a n/N: number for which a certain characteristic is present out of the total number of patients for which it was described